Although Alzheimer's disease, as a clinical-neuropathologic entity, was described 100 years ago by Alois Alzheimer, the preponderance of knowledge about the disease has accumulated since the 1970s. The dramatic advances in research during the last three decades propelled the disease from near obscurity to the forefront of modern biomedical science. The remarkable transformation of this field of study is reflected by the exponential increase in the number of investigators, publications, and funded projects. The current preeminence of dementia research is largely due to the increasing numbers and quality of significant breakthroughs in understanding the molecular neurobiology of the disease. Multiple promising leads have created an atmosphere of optimism about the prospects of discovering effective interventions to delay the progression of the disease. Some of the key factors that influenced the pace of progress and helped to change the "status" of dementia research were: a) increases in research funding, b) recruitment of new scientific talent, with a convergence of know-how and technologies, c) several crucial discoveries in molecular neurobiology, and d) National Institute on Aging initiatives to promote interdisciplinary research programs by creating a nationwide network of collaborating investigators and a research infrastructure/resource. This is an account of how the evolution of research into Alzheimer's disease occurred: a story about the critical findings, people, and public policies that influenced the amazing progress in understanding the underlying molecular mechanisms of the disease and in setting the stage for the discovery of a cure.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jalz.2007.04.379DOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
12
disease
8
public policies
8
molecular neurobiology
8
chapter development
4
development alzheimer's
4
disease case
4
case study
4
study public
4
policies development
4

Similar Publications

Age-related cognitive impairment and dementia pose a significant global health, social, and economic challenge. While Alzheimer's disease (AD) has historically been viewed as the leading cause of dementia, recent evidence reveals the considerable impact of vascular cognitive impairment and dementia (VCID), which now accounts for nearly half of all dementia cases. The Mediterranean diet-characterized by high consumption of fruits, vegetables, whole grains, fish, and olive oil-has been widely recognized for its cardiovascular benefits and may also reduce the risk of cognitive decline and dementia.

View Article and Find Full Text PDF

Microglial polarization and ferroptosis are important pathological features in Alzheimer's disease (AD). Ghrelin, a brain-gut hormone, has potential neuroprotective effects in AD. This study aimed to explore the potential mechanisms by which ghrelin regulates the progression of AD, as well as the crosstalk between microglial polarization and ferroptosis.

View Article and Find Full Text PDF

The long-term health of former athletes with a history of multiple concussions and/or repetitive head impact (RHI) exposure has been of growing interest among the public. The true proportion of dementia cases attributable to neurotrauma and the neurobehavioral profile/sequelae of multiple concussion and RHI exposure among athletes has been difficult to determine. Across three exposure paradigms (i.

View Article and Find Full Text PDF

Background: Edible insects are used for consumption and traditional medicine due to their rich bioactive compounds. This study examined the bioactive compounds and inhibitory effects of crude extracts from Bombyx mori and Omphisa fuscidentalis on α-glucosidase, α-amylase, acetylcholinesterase (AChE), and tyrosinase. Fatty acids, including n-hexadecanoic acid and oleic acid, were identified in the extracts and evaluated for their inhibitory potential against the enzymes in vitro and in silico.

View Article and Find Full Text PDF

From Antipsychotic to Neuroprotective: Computational Repurposing of Fluspirilene as a Potential PDE5 Inhibitor for Alzheimer's Disease.

J Comput Chem

January 2025

Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, New South Wales, Australia.

Phosphodiesterase 5 (PDE5) inhibitors have shown great potential in treating Alzheimer's disease by improving memory and cognitive function. In this study, we evaluated fluspirilene, a drug commonly used to treat schizophrenia, as a potential PDE5 inhibitor using computational methods. Molecular docking revealed that fluspirilene binds strongly to PDE5, supported by hydrophobic and aromatic interactions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!